SMS Pharmaceuticals Ltd

SMS Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

SMS Pharmaceuticals Ltd

₹ 214 5.35%
21 Feb - close price
smspharma.com BSE: 532815 NSE: SMSPHARMA
About

SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates.[1]

Key Points

Product Portfolio
It is an integrated pharmaceutical company specializing in Active Pharmaceutical Ingredients (API) and complex Intermediates, under various therapeutic categories including Anti-ulcer, anti-fungal, anti-migraine, anti-viral, anti-diabetic, anti-retroviral, etc. with global leadership position in 10+ therapeutic products. The company offers 45+ products to 800+ customers across 75+ countries. [1] [2]

Website BSE NSE
  • Market Cap ₹ 1,816 Cr.
  • Current Price ₹ 214
  • High / Low ₹ 398 / 140
  • Stock P/E 28.5
  • Book Value ₹ 70.6
  • Dividend Yield 0.19 %
  • ROCE 11.2 %
  • ROE 9.27 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is expected to give good quarter
  • Company has been maintaining a healthy dividend payout of 24.3%

Cons

  • Stock is trading at 3.04 times its book value
  • The company has delivered a poor sales growth of 8.81% over past five years.
  • Company has a low return on equity of 8.17% over last 3 years.
  • Debtor days have increased from 86.4 to 122 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Part of BSE SmallCap BSE Healthcare BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
121 61 64 159 149 149 135 167 161 246 164 197 173
94 65 65 146 131 126 109 139 133 212 131 165 140
Operating Profit 27 -4 -0 14 18 23 27 28 29 33 33 32 33
OPM % 22% -7% -1% 9% 12% 16% 20% 17% 18% 14% 20% 16% 19%
2 0 1 1 2 1 1 1 1 2 1 1 2
Interest 5 4 5 5 6 6 6 6 6 6 5 5 4
Depreciation 8 8 8 8 8 8 8 8 8 8 8 9 9
Profit before tax 17 -16 -12 1 6 11 13 15 16 22 22 20 23
Tax % 37% -156% -21% 12% 22% 24% 29% 21% 26% 26% 25% 28% 24%
11 9 -10 1 5 8 9 12 12 16 16 14 17
EPS in Rs 1.24 1.07 -1.16 0.09 0.59 0.95 1.10 1.42 1.44 1.88 1.93 1.68 2.03
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
248 518 587 611 438 463 465 412 563 520 522 709 780
284 461 500 522 363 369 375 332 442 405 467 592 648
Operating Profit -36 57 86 89 75 93 90 80 121 115 55 117 132
OPM % -14% 11% 15% 15% 17% 20% 19% 19% 22% 22% 10% 16% 17%
104 2 16 4 1 2 3 5 3 5 5 4 6
Interest 24 14 18 17 16 15 12 12 11 19 22 24 19
Depreciation 14 13 17 19 19 20 19 22 22 32 32 32 34
Profit before tax 30 32 67 56 42 60 62 51 91 69 6 66 86
Tax % 15% 36% 48% 26% 14% 33% 34% 36% 33% 1% 26% 25%
25 20 35 42 36 40 41 33 61 68 4 49 64
EPS in Rs 2.53 2.40 4.15 4.92 4.20 4.78 4.89 3.86 7.20 8.03 0.48 5.83 7.52
Dividend Payout % 8% 8% 5% 4% 5% 5% 5% 6% 4% 4% 62% 7%
Compounded Sales Growth
10 Years: 3%
5 Years: 9%
3 Years: 8%
TTM: 27%
Compounded Profit Growth
10 Years: 9%
5 Years: 4%
3 Years: -7%
TTM: 53%
Stock Price CAGR
10 Years: 18%
5 Years: 42%
3 Years: 31%
1 Year: 51%
Return on Equity
10 Years: 11%
5 Years: 10%
3 Years: 8%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 10 8 8 8 8 8 8 8 8 8 8 8 8
Reserves 234 213 246 286 254 293 331 359 420 485 487 562 589
149 167 167 204 149 146 144 157 255 263 254 281 285
79 120 119 158 89 72 93 103 147 126 165 217 286
Total Liabilities 471 509 540 656 501 519 577 627 830 883 914 1,068 1,169
147 247 277 370 290 279 281 280 457 438 412 437 426
CWIP 96 39 29 13 8 8 18 42 7 11 33 30 94
Investments 26 6 13 21 37 45 45 45 45 45 45 45 45
203 217 221 252 166 187 232 259 321 389 424 556 603
Total Assets 471 509 540 656 501 519 577 627 830 883 914 1,068 1,169

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-33 65 59 61 73 32 50 40 90 45 22 50
99 -37 -55 -79 -39 -17 -35 -43 -152 -27 -30 -52
-59 -30 -10 27 -33 -15 -13 -2 92 -12 -32 31
Net Cash Flow 7 -2 -6 9 1 0 2 -5 31 6 -39 29

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 52 39 37 36 18 19 20 43 68 34 104 122
Inventory Days 192 90 81 106 114 135 170 191 148 333 243 201
Days Payable 83 59 58 79 82 49 59 66 70 97 117 130
Cash Conversion Cycle 161 70 61 63 50 105 131 169 146 270 230 192
Working Capital Days 126 65 62 63 48 73 95 111 115 172 196 167
ROCE % -12% 12% 21% 16% 13% 18% 16% 13% 17% 12% 4% 11%

Shareholding Pattern

Numbers in percentages

Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
67.29% 64.17% 64.17% 64.17% 64.29% 64.32% 64.32% 64.32% 64.67% 64.67% 64.67% 64.67%
0.61% 0.63% 0.59% 0.59% 0.59% 0.67% 0.60% 0.59% 0.17% 0.18% 0.52% 0.31%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.98% 2.13% 2.55% 2.55%
32.10% 35.20% 35.23% 35.23% 35.12% 35.01% 35.07% 35.10% 33.18% 33.03% 32.27% 32.47%
No. of Shareholders 27,51626,63826,49126,52625,53724,65325,24625,34130,14031,78033,13634,973

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls